OSAKA, Japan I July 22, 2019 I Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it has entered into an out- licensing agreement on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa, with the AMR Centre Ltd. (Base: Alderley Park, Cheshire, the UK; hereafter “AMR Centre”).
Pseudomonas aeruginosa has remarkable ability to acquire resistance to antibiotics. As a consequence, the anti-pseudomonal agents that can be used against Pseudomonas aeruginosa infections and its infection-control measures are relatively limited 1. COT-143 is a humanized monoclonal antibody targeting the PcrV protein, which is involved in pathogenicity of Pseudomonas aeruginosa. Many non-clinical trials have demonstrated that COT-143 is effective in treatment and prevention of infection caused by Pseudomonas aeruginosa including multidrug-resistant one.
The AMR Centre was established in the UK to accelerate the development of novel antibiotics. With the completion of this new agreement, The AMR Centre will hold the exclusive worldwide right of research, development and manufacturing of COT-143. Shionogi will confirm development plans made by the AMR Centre and their progress, and will continue to negotiate a future sales agreement.
Dwindling supply of antibiotics continues to pose a grave threat to global health. Projects such as COT-143 are an example of excellent research struggling to progress in the context of market failure around the development of new antibiotics. Shionogi expects that the AMR Centre bridges that gap and gets these programs moving forward utilizing its fully integrated development capacity including various foundations and medical networks. The AMR Centre is in discussions about conducting phase 1 and phase 2 clinical trials at the Royal Liverpool University Hospital in 2020.
Shionogi has its vision, “Grow sustainably as a drug discovery-based pharmaceutical company, contributing to a more vigorous society through improving healthcare”, and is striving to contribute to the better health and QOL of people all over the world by promoting open innovation with creative companies and academia in addition to our own R&D activities. Shionogi will also promote development of medications for treatment of drug-resistant infections which has become a global issue through cooperation with external partners.
[About the AMR Centre]
Established in May 2016, the AMR Centre is a key part of the UK’s response to the global threat from antimicrobial resistance. Based at Alderley Park in the UK, the AMR Centre is a company with public and private investors, to support/accelerate the development of new antibiotics through a fully integrated development capability, offering translational R&D through to clinical proof of concept.
Please see https://www.amrcentre.com/ for further information.
1. http://amr.ncgm.go.jp/medics/2-1-3.html Website of AMR Clinical Reference Centre
SOURCE: Shionogi
Post Views: 300
OSAKA, Japan I July 22, 2019 I Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that it has entered into an out- licensing agreement on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa, with the AMR Centre Ltd. (Base: Alderley Park, Cheshire, the UK; hereafter “AMR Centre”).
Pseudomonas aeruginosa has remarkable ability to acquire resistance to antibiotics. As a consequence, the anti-pseudomonal agents that can be used against Pseudomonas aeruginosa infections and its infection-control measures are relatively limited 1. COT-143 is a humanized monoclonal antibody targeting the PcrV protein, which is involved in pathogenicity of Pseudomonas aeruginosa. Many non-clinical trials have demonstrated that COT-143 is effective in treatment and prevention of infection caused by Pseudomonas aeruginosa including multidrug-resistant one.
The AMR Centre was established in the UK to accelerate the development of novel antibiotics. With the completion of this new agreement, The AMR Centre will hold the exclusive worldwide right of research, development and manufacturing of COT-143. Shionogi will confirm development plans made by the AMR Centre and their progress, and will continue to negotiate a future sales agreement.
Dwindling supply of antibiotics continues to pose a grave threat to global health. Projects such as COT-143 are an example of excellent research struggling to progress in the context of market failure around the development of new antibiotics. Shionogi expects that the AMR Centre bridges that gap and gets these programs moving forward utilizing its fully integrated development capacity including various foundations and medical networks. The AMR Centre is in discussions about conducting phase 1 and phase 2 clinical trials at the Royal Liverpool University Hospital in 2020.
Shionogi has its vision, “Grow sustainably as a drug discovery-based pharmaceutical company, contributing to a more vigorous society through improving healthcare”, and is striving to contribute to the better health and QOL of people all over the world by promoting open innovation with creative companies and academia in addition to our own R&D activities. Shionogi will also promote development of medications for treatment of drug-resistant infections which has become a global issue through cooperation with external partners.
[About the AMR Centre]
Established in May 2016, the AMR Centre is a key part of the UK’s response to the global threat from antimicrobial resistance. Based at Alderley Park in the UK, the AMR Centre is a company with public and private investors, to support/accelerate the development of new antibiotics through a fully integrated development capability, offering translational R&D through to clinical proof of concept.
Please see https://www.amrcentre.com/ for further information.
1. http://amr.ncgm.go.jp/medics/2-1-3.html Website of AMR Clinical Reference Centre
SOURCE: Shionogi
Post Views: 300
